Published in Epilepsia on February 03, 2010
Cannabinoids and Epilepsy. Neurotherapeutics (2015) 0.91
Target-dependent control of synaptic inhibition by endocannabinoids in the thalamus. J Neurosci (2011) 0.81
Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats. Neuropharmacology (2012) 0.80
Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats. Neuropharmacology (2014) 0.80
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Gender differences in drug responses. Pharmacol Res (2006) 2.50
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet (2002) 2.20
Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A (2005) 2.13
ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem (2005) 2.11
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med (2010) 2.10
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A (2013) 1.94
Beta-amyloid monomers are neuroprotective. J Neurosci (2009) 1.87
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol (2007) 1.85
Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry (2007) 1.79
Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology (2011) 1.76
Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci U S A (2009) 1.75
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem (2004) 1.73
Evolving concepts on the pathophysiology of absence seizures: the cortical focus theory. Arch Neurol (2005) 1.72
Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem (2006) 1.71
Synaptic inhibition of Purkinje cells mediates consolidation of vestibulo-cerebellar motor learning. Nat Neurosci (2009) 1.66
Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci (2004) 1.66
Transport infrastructure surveillance and monitoring by electromagnetic sensing: the ISTIMES project. Sensors (Basel) (2010) 1.60
Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci (2005) 1.57
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
StochKit2: software for discrete stochastic simulation of biochemical systems with events. Bioinformatics (2011) 1.52
Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) (2009) 1.50
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology (2005) 1.49
In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle (2011) 1.46
Vitamin D3: a helpful immuno-modulator. Immunology (2011) 1.46
Functional characterization of WNT7A signaling in PC12 cells: interaction with A FZD5 x LRP6 receptor complex and modulation by Dickkopf proteins. J Biol Chem (2003) 1.44
Comparative evaluation of simple indices of insulin resistance. Metabolism (2004) 1.42
Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci (2006) 1.42
Akt as a therapeutic target in cancer. Expert Opin Ther Targets (2008) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
Editorial. Curr Neuropharmacol (2006) 1.40
TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res (2008) 1.40
The conditioned eyeblink reflex: a potential tool for the detection of cerebellar dysfunction in multiple sclerosis. Mult Scler (2011) 1.39
Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol Rev (2008) 1.38
The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci (2007) 1.38
Chlorogenic acid inhibits lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells through suppressing NF-kappaB and JNK/AP-1 activation. Int Immunopharmacol (2009) 1.37
Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology (2005) 1.36
Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J Neurosci (2005) 1.32
A revised Racine's scale for PTZ-induced seizures in rats. Physiol Behav (2009) 1.32
Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther (2006) 1.31
Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology (2006) 1.28
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res (2008) 1.26
Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc Natl Acad Sci U S A (2009) 1.25
Onset and propagation of spike and slow wave discharges in human absence epilepsy: A MEG study. Epilepsia (2009) 1.22
Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology (2012) 1.21
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol (2009) 1.20
Genetic dissection of the function of hindbrain axonal commissures. PLoS Biol (2010) 1.18
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle (2010) 1.18
The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci (2003) 1.17
Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry (2009) 1.17
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (2011) 1.17
Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol (2009) 1.16
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget (2011) 1.16
Emerging MEK inhibitors. Expert Opin Emerg Drugs (2010) 1.16
Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) (2005) 1.15
Induction of the Wnt inhibitor, Dickkopf-1, is associated with neurodegeneration related to temporal lobe epilepsy. Epilepsia (2007) 1.14
Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n-6 and n-3 fatty acids? Nutr Metab Cardiovasc Dis (2006) 1.14
The WAG/Rij strain: a genetic animal model of absence epilepsy with comorbidity of depression [corrected]. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.14
Induction of the Wnt antagonist, Dickkopf-1, contributes to the development of neuronal death in models of brain focal ischemia. J Cereb Blood Flow Metab (2008) 1.13
Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med (2003) 1.11
Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol (2005) 1.09
2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab (2012) 1.09
Postprandial increase of oleoylethanolamide mobilization in small intestine of the Burmese python (Python molurus). Am J Physiol Regul Integr Comp Physiol (2005) 1.09
Resistance to TRAIL and how to surmount it. Immunol Res (2012) 1.08
Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats. PLoS One (2008) 1.08
[Identify nature N-acylethanolamide-hydrolyzing acid amide (NAAA) inhibitor: effect of angelicae pubescentis radix on anti-inflammation]. Zhongguo Zhong Yao Za Zhi (2011) 1.07
Hindbrain noradrenergic input to the hypothalamic PVN mediates the activation of oxytocinergic neurons induced by the satiety factor oleoylethanolamide. Am J Physiol Endocrinol Metab (2013) 1.07
Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci (2006) 1.06
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol (2008) 1.05
Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci U S A (2003) 1.05
Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J Neurochem (2004) 1.05
TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway. Neurobiol Dis (2008) 1.04
The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. J Neurosci (2010) 1.04
BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology (2012) 1.04
Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterations. Int Rev Neurobiol (2009) 1.04
Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem (2003) 1.03
Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. Neuropharmacology (2012) 1.03
The satiety signal oleoylethanolamide stimulates oxytocin neurosecretion from rat hypothalamic neurons. Peptides (2013) 1.02
Metabotropic glutamate receptors in glial cells. Neurochem Res (2008) 1.02
Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects. Pharmacol Rev (2004) 1.02
Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One (2011) 1.01
Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol (2009) 1.01